Gene · 51185
Papers2,935
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
1,181 to 1,200 of 2,935
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Catchet-MS identifies IKZF1-targeting thalidomide analogues as novel HIV-1 latency reversal agents. | Nucleic Acids Res | 2022 | 35640596 | PubTator, text mining | PubMed |
| Phenotypic drug discovery: recent successes, lessons learned and new directions. | Nat Rev Drug Discov | 2022 | 35637317 | PubTator, text mining | PubMed |
| High-risk disease in newly diagnosed multiple myeloma: beyond the R-ISS and IMWG definitions. | Blood Cancer J | 2022 | 35637223 | PubTator, text mining | PubMed |
| Structure-based rational design enables efficient discovery of a new selective and potent AKT PROTAC degrader. | Eur J Med Chem | 2022 | 35635954 | PubTator, text mining | PubMed |
| 3,6'- and 1,6'-Dithiopomalidomide Mitigate Ischemic Stroke in Rats and Blunt Inflammation. | Pharmaceutics | 2022 | 35631536 | PubTator, text mining | PubMed |
| The Role of DNA Repair in Genomic Instability of Multiple Myeloma. | Int J Mol Sci | 2022 | 35628498 | PubTator, text mining | PubMed |
| Antitumoral Activity of a CDK9 PROTAC Compound in HER2-Positive Breast Cancer. | Int J Mol Sci | 2022 | 35628286 | PubTator, text mining | PubMed |
| Overview of Neural Tube Defects: Gene-Environment Interactions, Preventative Approaches and Future Perspectives. | Biomedicines | 2022 | 35625701 | PubTator, text mining | PubMed |
| Proceedings from the Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Immune and Cellular Therapy in Multiple Myeloma. | Transplant Cell Ther | 2022 | 35605882 | PubTator, text mining | PubMed |
| Recent advances in IAP-based PROTACs (SNIPERs) as potential therapeutic agents. | J Enzyme Inhib Med Chem | 2022 | 35589670 | PubTator, text mining | PubMed |
| Pomalidomide- and dexamethasone-based regimens in the treatment of refractory/relapsed multiple myeloma. | Ther Adv Hematol | 2022 | 35585966 | PubTator, text mining | PubMed |
| Increasing genomic discovery in newly diagnosed multiple myeloma: defining disease biology and its correlation to risk. | Ann Hematol | 2022 | 35585246 | PubTator, text mining | PubMed |
| Interactome of Aiolos/Ikaros Reveals Combination Rationale of Cereblon Modulators with HDAC Inhibitors in DLBCL. | Clin Cancer Res | 2022 | 35583604 | PubTator, text mining | PubMed |
| Drug resistance and minimal residual disease in multiple myeloma. | Cancer Drug Resist | 2022 | 35582527 | PubTator, text mining | PubMed |
| Del(5q) and inv(3) in myelodysplastic syndrome: A rare case report. | World J Clin Cases | 2022 | 35582053 | PubTator, text mining | PubMed |
| Feasibility and clinical utility of comprehensive genomic profiling of hematological malignancies. | Cancer Sci | 2022 | 35579198 | PubTator, text mining | PubMed |
| Development of a potent small-molecule degrader against oncogenic BRAFV600E protein that evades paradoxical MAPK activation. | Cancer Sci | 2022 | 35579105 | PubTator, text mining | PubMed |
| The Leading Role of the Immune Microenvironment in Multiple Myeloma: A New Target with a Great Prognostic and Clinical Value. | J Clin Med | 2022 | 35566637 | PubTator, text mining | PubMed |
| Multivariant Transcriptome Analysis Identifies Modules and Hub Genes Associated with Poor Outcomes in Newly Diagnosed Multiple Myeloma Patients. | Cancers (Basel) | 2022 | 35565356 | PubTator, text mining | PubMed |
| Unveiling the Role of the Tumor Microenvironment in the Treatment of Follicular Lymphoma. | Cancers (Basel) | 2022 | 35565286 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/51185/papers?page=60